Artesunate–amodiaquine and artemether–lumefantrine for the treatment of uncomplicated falciparum malaria in Liberia: in vivo efficacy and frequency of molecular markers
Abstract Background Artesunate–amodiaquine (ASAQ) and Artemether–lumefantrine (AL) are the recommended treatment for uncomplicated Plasmodium falciparum malaria in Liberia. Intermittent preventive treatment with sulfadoxine/pyrimethamine is also recommended for pregnant women. The therapeutic effica...
Published in: | Malaria Journal |
---|---|
Main Authors: | , , , , , , , , , , , , , , |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
BMC
2022
|
Subjects: | |
Online Access: | https://doi.org/10.1186/s12936-022-04140-7 https://doaj.org/article/405018a636c24806a5ef73c716f54617 |
id |
ftdoajarticles:oai:doaj.org/article:405018a636c24806a5ef73c716f54617 |
---|---|
record_format |
openpolar |
spelling |
ftdoajarticles:oai:doaj.org/article:405018a636c24806a5ef73c716f54617 2023-05-15T15:17:22+02:00 Artesunate–amodiaquine and artemether–lumefantrine for the treatment of uncomplicated falciparum malaria in Liberia: in vivo efficacy and frequency of molecular markers Victor S. Koko Marian Warsame Benjamin Vonhm Moses K. Jeuronlon Didier Menard Laurence Ma Fahn Taweh Lekilay Tehmeh Paye Nyansaiye Oliver J. Pratt Sei Parwon Patrick Kamara Magnus Asinya Aaron Kollie Pascal Ringwald 2022-04-01T00:00:00Z https://doi.org/10.1186/s12936-022-04140-7 https://doaj.org/article/405018a636c24806a5ef73c716f54617 EN eng BMC https://doi.org/10.1186/s12936-022-04140-7 https://doaj.org/toc/1475-2875 doi:10.1186/s12936-022-04140-7 1475-2875 https://doaj.org/article/405018a636c24806a5ef73c716f54617 Malaria Journal, Vol 21, Iss 1, Pp 1-15 (2022) Artesunate–amodiaquine Artemether–lumefantrine Plasmodium falciparum Efficacy Molecular markers of antimalarial drug resistance Liberia Arctic medicine. Tropical medicine RC955-962 Infectious and parasitic diseases RC109-216 article 2022 ftdoajarticles https://doi.org/10.1186/s12936-022-04140-7 2022-12-30T22:20:55Z Abstract Background Artesunate–amodiaquine (ASAQ) and Artemether–lumefantrine (AL) are the recommended treatment for uncomplicated Plasmodium falciparum malaria in Liberia. Intermittent preventive treatment with sulfadoxine/pyrimethamine is also recommended for pregnant women. The therapeutic efficacy of Artesunate–amodiaquine and Artemether–lumefantrine, and the frequency of molecular markers associated with anti-malarial drug resistance were investigated. Methods The therapeutic efficacy of ASAQ and AL was evaluated using the standard World Health Organization protocol (WHO. Methods for Surveillance of Antimalarial Drug Efficacy. Geneva: World Health Organization; 2009. https://www.who.int/malaria/publications/atoz/9789241597531/en/ ). Eligible children were recruited and monitored clinically and parasitologically for 28 days. Polymorphisms in the Pfkelch 13, chloroquine resistance transporter (Pfcrt), multidrug resistance 1 (Pfmdr-1), dihydrofolate reductase (Pfdhfr), and dihydropteroate synthase (Pfdhps) genes and copy number variations in the plasmepsin-2 (Pfpm2) gene were assessed in pretreatment samples. Results Of the 359 children enrolled, 180 were treated with ASAQ (89 in Saclepea and 91 in Bensonville) and 179 with AL (90 in Sinje and 89 in Kakata). Of the recruited children, 332 (92.5%) reached study endpoints. PCR-corrected per-protocol analysis showed ACPR of 90.2% (95% CI: 78.6–96.7%) in Bensonville and 92.7% (95% CI: 83.4.8–96.5%) in Saclepea for ASAQ, while ACPR of 100% was observed in Kakata and Sinje for AL. In both treatment groups, only two patients had parasites on day 3. No artemisinin resistance associated Pfkelch13 mutations or multiple copies of Pfpm2 were found. Most samples tested had the Pfcrt 76 T mutation (80/91, 87.9%), while the Pfmdr-1 86Y (40/91, 44%) and 184F (47/91, 51.6%) mutations were less frequent. The Pfdhfr triple mutant (51I/59R/108 N) was the predominant allele (49.2%). For the Pfdhps gene, it was the 540E mutant (16.0%), and the 436A mutant (14.3%). The quintuple ... Article in Journal/Newspaper Arctic Directory of Open Access Journals: DOAJ Articles Arctic Malaria Journal 21 1 |
institution |
Open Polar |
collection |
Directory of Open Access Journals: DOAJ Articles |
op_collection_id |
ftdoajarticles |
language |
English |
topic |
Artesunate–amodiaquine Artemether–lumefantrine Plasmodium falciparum Efficacy Molecular markers of antimalarial drug resistance Liberia Arctic medicine. Tropical medicine RC955-962 Infectious and parasitic diseases RC109-216 |
spellingShingle |
Artesunate–amodiaquine Artemether–lumefantrine Plasmodium falciparum Efficacy Molecular markers of antimalarial drug resistance Liberia Arctic medicine. Tropical medicine RC955-962 Infectious and parasitic diseases RC109-216 Victor S. Koko Marian Warsame Benjamin Vonhm Moses K. Jeuronlon Didier Menard Laurence Ma Fahn Taweh Lekilay Tehmeh Paye Nyansaiye Oliver J. Pratt Sei Parwon Patrick Kamara Magnus Asinya Aaron Kollie Pascal Ringwald Artesunate–amodiaquine and artemether–lumefantrine for the treatment of uncomplicated falciparum malaria in Liberia: in vivo efficacy and frequency of molecular markers |
topic_facet |
Artesunate–amodiaquine Artemether–lumefantrine Plasmodium falciparum Efficacy Molecular markers of antimalarial drug resistance Liberia Arctic medicine. Tropical medicine RC955-962 Infectious and parasitic diseases RC109-216 |
description |
Abstract Background Artesunate–amodiaquine (ASAQ) and Artemether–lumefantrine (AL) are the recommended treatment for uncomplicated Plasmodium falciparum malaria in Liberia. Intermittent preventive treatment with sulfadoxine/pyrimethamine is also recommended for pregnant women. The therapeutic efficacy of Artesunate–amodiaquine and Artemether–lumefantrine, and the frequency of molecular markers associated with anti-malarial drug resistance were investigated. Methods The therapeutic efficacy of ASAQ and AL was evaluated using the standard World Health Organization protocol (WHO. Methods for Surveillance of Antimalarial Drug Efficacy. Geneva: World Health Organization; 2009. https://www.who.int/malaria/publications/atoz/9789241597531/en/ ). Eligible children were recruited and monitored clinically and parasitologically for 28 days. Polymorphisms in the Pfkelch 13, chloroquine resistance transporter (Pfcrt), multidrug resistance 1 (Pfmdr-1), dihydrofolate reductase (Pfdhfr), and dihydropteroate synthase (Pfdhps) genes and copy number variations in the plasmepsin-2 (Pfpm2) gene were assessed in pretreatment samples. Results Of the 359 children enrolled, 180 were treated with ASAQ (89 in Saclepea and 91 in Bensonville) and 179 with AL (90 in Sinje and 89 in Kakata). Of the recruited children, 332 (92.5%) reached study endpoints. PCR-corrected per-protocol analysis showed ACPR of 90.2% (95% CI: 78.6–96.7%) in Bensonville and 92.7% (95% CI: 83.4.8–96.5%) in Saclepea for ASAQ, while ACPR of 100% was observed in Kakata and Sinje for AL. In both treatment groups, only two patients had parasites on day 3. No artemisinin resistance associated Pfkelch13 mutations or multiple copies of Pfpm2 were found. Most samples tested had the Pfcrt 76 T mutation (80/91, 87.9%), while the Pfmdr-1 86Y (40/91, 44%) and 184F (47/91, 51.6%) mutations were less frequent. The Pfdhfr triple mutant (51I/59R/108 N) was the predominant allele (49.2%). For the Pfdhps gene, it was the 540E mutant (16.0%), and the 436A mutant (14.3%). The quintuple ... |
format |
Article in Journal/Newspaper |
author |
Victor S. Koko Marian Warsame Benjamin Vonhm Moses K. Jeuronlon Didier Menard Laurence Ma Fahn Taweh Lekilay Tehmeh Paye Nyansaiye Oliver J. Pratt Sei Parwon Patrick Kamara Magnus Asinya Aaron Kollie Pascal Ringwald |
author_facet |
Victor S. Koko Marian Warsame Benjamin Vonhm Moses K. Jeuronlon Didier Menard Laurence Ma Fahn Taweh Lekilay Tehmeh Paye Nyansaiye Oliver J. Pratt Sei Parwon Patrick Kamara Magnus Asinya Aaron Kollie Pascal Ringwald |
author_sort |
Victor S. Koko |
title |
Artesunate–amodiaquine and artemether–lumefantrine for the treatment of uncomplicated falciparum malaria in Liberia: in vivo efficacy and frequency of molecular markers |
title_short |
Artesunate–amodiaquine and artemether–lumefantrine for the treatment of uncomplicated falciparum malaria in Liberia: in vivo efficacy and frequency of molecular markers |
title_full |
Artesunate–amodiaquine and artemether–lumefantrine for the treatment of uncomplicated falciparum malaria in Liberia: in vivo efficacy and frequency of molecular markers |
title_fullStr |
Artesunate–amodiaquine and artemether–lumefantrine for the treatment of uncomplicated falciparum malaria in Liberia: in vivo efficacy and frequency of molecular markers |
title_full_unstemmed |
Artesunate–amodiaquine and artemether–lumefantrine for the treatment of uncomplicated falciparum malaria in Liberia: in vivo efficacy and frequency of molecular markers |
title_sort |
artesunate–amodiaquine and artemether–lumefantrine for the treatment of uncomplicated falciparum malaria in liberia: in vivo efficacy and frequency of molecular markers |
publisher |
BMC |
publishDate |
2022 |
url |
https://doi.org/10.1186/s12936-022-04140-7 https://doaj.org/article/405018a636c24806a5ef73c716f54617 |
geographic |
Arctic |
geographic_facet |
Arctic |
genre |
Arctic |
genre_facet |
Arctic |
op_source |
Malaria Journal, Vol 21, Iss 1, Pp 1-15 (2022) |
op_relation |
https://doi.org/10.1186/s12936-022-04140-7 https://doaj.org/toc/1475-2875 doi:10.1186/s12936-022-04140-7 1475-2875 https://doaj.org/article/405018a636c24806a5ef73c716f54617 |
op_doi |
https://doi.org/10.1186/s12936-022-04140-7 |
container_title |
Malaria Journal |
container_volume |
21 |
container_issue |
1 |
_version_ |
1766347611154939904 |